EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Nanoparticle-based Drug Delivery for Pulmonary Tuberculosis: A Systematic Review on Enhanced Treatment Outcomes, Cellular Uptake, Safety, and Immunomodulatory Potential

Malik Saim Jameel, Alveena Mushtaq Malik

Journal of Science, Technology, Education, Art and Medicine · 15.12.2025 · 2 (2) · 82-101

DOI: 10.63137/jsteam.357341 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Science, Technology, Education, Art and Medicine, online erschienen am 15.12.2025. Verfasst von Malik Saim Jameel und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This systematic review critically evaluates nanoparticle-based drug delivery systems (NDDS) for pulmonary tuberculosis (TB), emphasizing their therapeutic efficacy, intracellular targeting capabilities, safety, and translational potential via inhalational routes.

Methods

A systematic search of databases, including PubMed, ScienceDirect, Springer, and institutional repositories, was conducted for studies published between January 2013 and December 2024. The Inclusion criteria encompassed nanoparticle formulations targeting Mycobacterium tuberculosis via pulmonary delivery with reported in vitro, ex vivo, or in vivo outcomes. Quality and bias were assessed using adapted SYRCLE and Cochrane RoB 2 tools. A total of 15 high-quality studies were selected from 187 records that were initially screened.

Results

Nanoparticles, including metallic (Ag, ZnO), polymeric (PES, mannosylated gelatin), and lipid-based (SLNs, NLCs), demonstrated enhanced drug bioavailability, macrophage uptake, and bactericidal activity against drug-sensitive and multidrug-resistant TB strains. In vivo studies showed superior lung deposition, reduced bacterial load, and minimized systemic toxicity via pulmonary delivery. Functionalization strategies like mannosylation improved intracellular uptake. However, concerns remain regarding nanoparticle cytotoxicity, long-term safety, formulation stability, and inadequate pharmacokinetic profiling.

Conclusion

NDDS for pulmonary TB exhibits significant potential to overcome limitations of conventional therapies by enabling targeted, sustained, and safer drug delivery. Pulmonary and intracellular targeting approaches show strong preclinical efficacy, but translational progress is limited by safety and regulatory gaps. Future research must focus on standardized toxicology, in vivo pharmacokinetics, and clinical trials to establish these platforms as frontline TB therapies.

Zitieren

APA

Jameel, M. S., & Malik, A. M. (2025). Nanoparticle-based Drug Delivery for Pulmonary Tuberculosis: A Systematic Review on Enhanced Treatment Outcomes, Cellular Uptake, Safety, and Immunomodulatory Potential. Journal of Science, Technology, Education, Art and Medicine, 2(2), 82-101. https://doi.org/10.63137/jsteam.357341

Vancouver

Jameel MS, Malik AM. Nanoparticle-based Drug Delivery for Pulmonary Tuberculosis: A Systematic Review on Enhanced Treatment Outcomes, Cellular Uptake, Safety, and Immunomodulatory Potential. Journal of Science, Technology, Education, Art and Medicine. 2025;2(2):82-101. doi:10.63137/jsteam.357341

BibTeX
@article{Jameel2025,
  author = {Jameel, Malik Saim and Malik, Alveena Mushtaq},
  title = {Nanoparticle-based Drug Delivery for Pulmonary Tuberculosis: A Systematic Review on Enhanced Treatment Outcomes, Cellular Uptake, Safety, and Immunomodulatory Potential},
  journal = {Journal of Science, Technology, Education, Art and Medicine},
  year = {2025},
  volume = {2},
  number = {2},
  pages = {82--101},
  doi = {10.63137/jsteam.357341}
}
Kostenlos starten →